Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 3/20 | 0.34 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.31 |
| ▸ | PI4KB | Q9UBF8 | 3/20 | 0.30 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.30 |
| ▸ | PIK3C2A | O00443 | 1/20 | 0.30 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.30 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.30 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.30 |
| ▸ | CDK9 | P50750 | 1/20 | 0.30 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.30 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1244953 | 1.00 | EPHX1 (0.34) | EPHX1GABRR1PI4KBPIK3CDPIK3C2A | |
| SCHEMBL13180020 | 1.00 | EPHX1 (0.34) | EPHX1GABRR1PI4KBPIK3CDPIK3C2A | |
| Hydrochloric Acid SCHEMBL27736853 | 0.98 | EPHX1 (0.36) | EPHX1GABRR1 | |
| SCHEMBL1766393 | 0.81 | EPHX1 (0.30) | EPHX1 | |
| SCHEMBL1642423 | 0.78 | GABRR1 (0.34) | EPHX1GABRR1 | |
| SCHEMBL12867359 | 0.77 | CA1 (0.33) | EPHX1GABRR1 | |
| SCHEMBL12885928 | 0.77 | GABRR1 (0.42) | GABRR1 | |
| SCHEMBL301118 | 0.77 | GABRR1 (0.42) | GABRR1 | |
| SCHEMBL14281509 | 0.77 | ALDH1A1 (0.32) | HTT | |
| SCHEMBL10164157 | 0.77 | CA1 (0.33) | EPHX1GABRR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9533986-B2 | Bicyclic dihydropyridone kinase inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2017-01-03 | — | — | US | disclosed |
| US-9469654-B2 | Bicyclic oxa-lactam kinase inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2016-10-18 | — | — | US | disclosed |
| US-9469654-B2 | Bicyclic oxa-lactam kinase inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2016-10-18 | — | — | US | disclosed |
| US-20150252056-A1 | BICYCLIC OXA-LACTAM KINASE INHIBITORS | ALEXION PHARMACEUTICALS, INC. | 2015-09-10 | — | — | US | disclosed |
| US-20150252056-A1 | BICYCLIC OXA-LACTAM KINASE INHIBITORS | ALEXION PHARMACEUTICALS, INC. | 2015-09-10 | — | — | US | disclosed |
| US-20120322761-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-12-20 | — | — | US | disclosed |
| US-8304403-B2 | Heterocyclic CETP inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-06 | — | — | US | disclosed |
| US-7888376-B2 | Cholesteryl ester transfer protein (CETP) inhibitors; atherosclerosis and cardiovascular diseases; N-(1-(5-chloropyridin-2-yl)-1-(3-fluoro-5-(trifluoromethyl)phenyl)-2-phenylethyl)-4-(trifluoromethyl)thiazol-2-amine; Alzheimer's, atherosclerosis, venous thrombosis, peripheral vascular disease | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-02-15 | — | — | US | disclosed |
| US-20100267669-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-10-21 | — | — | US | disclosed |
| US-7790770-B2 | Heterocyclic CETP inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-09-07 | — | — | US | disclosed |
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-07-12 | — | — | US | disclosed |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
| WO-2007062314-A2 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007062308-A2 | HOMO- AND HETEROCYCLIC COMPOUNDS SUITABLE AS CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-31 | — | — | WO | disclosed |
| JP-2006347930-A | OPTICALLY ACTIVE BUTYL AMINE | MITSUBISHI PHARMA CORP | 2006-12-28 | — | — | JP | disclosed |
| EP-0489548-B1 | A process for the preparation of 2(R)-methyl-4,4,4-trifluorobutylamine, intermediates, and a process for the preparation of a derivative thereof | ZENECA LTD (GB) | 1994-12-14 | — | — | EP | disclosed |
| US-5274118-A | Process for preparing (2R)-methyl-4,4,4-trifluorobutylamine | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-12-28 | — | — | US | disclosed |
| EP-0489548-A1 | A process for the preparation of 2(R)-methyl-4,4,4-trifluorobutylamine, intermediates, and a process for the preparation of a derivative thereof | ZENECA LIMITED (GB) | 1992-06-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | EPHX1 1130/4885GABRR1 4319/4885PI4KB 800/4885 |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | EPHX1 1130/4885GABRR1 4319/4885PI4KB 800/4885 |
| US-20150252056-A1 | BICYCLIC OXA-LACTAM KINASE INHIBITORS | SYK, BTK, JAK2 | EPHX1 2838/4885GABRR1 1420/4885PI4KB 165/4885 |
| US-20120322761-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | EPHX1 1130/4885GABRR1 4319/4885PI4KB 800/4885 |
| US-20100267669-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | EPHX1 1130/4885GABRR1 4319/4885PI4KB 800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.